复发性-话题@MedSci

#复发性#

452篇内容 | 2489人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1909726, encodeId=aaef1909e2610, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Gastroenterology：戊酸、粪便微生物移植与复发性梭状芽胞杆菌感染, objectType=article, longId=144686, objectId=f860144686b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f860144686b8, replyNumber=0, likeNumber=60, createdTime=2018-12-24, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f860144686b8, moduleTitle=Gastroenterology：戊酸、粪便微生物移植与复发性梭状芽胞杆菌感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f860144686b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909747, encodeId=03d51909e4746, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Lancet oncol：Axicabtagene ciloleucel（自体抗CD19嵌合抗原受体T细胞疗法）治疗复发性/难治性大B细胞淋巴瘤的长期安全性和疗, objectType=article, longId=155389, objectId=074b15538986, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=074b15538986, replyNumber=0, likeNumber=89, createdTime=2019-06-17, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=074b15538986, moduleTitle=Lancet oncol：Axicabtagene ciloleucel（自体抗CD19嵌合抗原受体T细胞疗法）治疗复发性/难治性大B细胞淋巴瘤的长期安全性和疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=074b15538986)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909731, encodeId=28d71909e31ae, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Lancet oncol：色瑞替尼联合吉西他滨用于原发性难治性或复发性霍奇金淋巴瘤的安全性评估, objectType=article, longId=146860, objectId=713314686070, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=713314686070, replyNumber=0, likeNumber=122, createdTime=2019-07-09, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=713314686070, moduleTitle=Lancet oncol：色瑞替尼联合吉西他滨用于原发性难治性或复发性霍奇金淋巴瘤的安全性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=713314686070)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909721, encodeId=79251909e2189, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=一例复发性胃出血的罕见原因, objectType=article, longId=141415, objectId=bc8014141502, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc8014141502, replyNumber=0, likeNumber=72, createdTime=2018-12-14, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc8014141502, moduleTitle=一例复发性胃出血的罕见原因, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc8014141502)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909746, encodeId=b9471909e46d5, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=JAMA Intern Med：减少复发性尿路感染反复多喝水能少吃药？！, objectType=article, longId=155323, objectId=b6c5155323fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6c5155323fe, replyNumber=0, likeNumber=56, createdTime=2019-05-08, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6c5155323fe, moduleTitle=JAMA Intern Med：减少复发性尿路感染反复多喝水能少吃药？！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6c5155323fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909728, encodeId=e6c71909e28b1, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Blood：复发性或难治性结节性淋巴细胞为主型霍奇金淋巴瘤的更佳治疗方案, objectType=article, longId=145707, objectId=7eea145e07b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7eea145e07b9, replyNumber=0, likeNumber=60, createdTime=2018-12-09, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7eea145e07b9, moduleTitle=Blood：复发性或难治性结节性淋巴细胞为主型霍奇金淋巴瘤的更佳治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7eea145e07b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909735, encodeId=a8911909e3544, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Stroke：升高的中性粒细胞和存在颅内动脉狭窄增加了复发性卒中的风险, objectType=article, longId=148206, objectId=6577148206c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6577148206c6, replyNumber=0, likeNumber=76, createdTime=2019-04-02, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6577148206c6, moduleTitle=Stroke：升高的中性粒细胞和存在颅内动脉狭窄增加了复发性卒中的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6577148206c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909713, encodeId=7e211909e13d8, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Blood：PD-1封闭可提高复发性/难治性经典霍奇金淋巴瘤患者的缓解率，并延长其缓解时间，但会增加其免疫毒性风险, objectType=article, longId=137130, objectId=1f0113e13038, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f0113e13038, replyNumber=0, likeNumber=82, createdTime=2018-11-14, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f0113e13038, moduleTitle=Blood：PD-1封闭可提高复发性/难治性经典霍奇金淋巴瘤患者的缓解率，并延长其缓解时间，但会增加其免疫毒性风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f0113e13038)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909743, encodeId=99921909e433f, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Blood：Selinexor联合低剂量硼替佐米和地塞米松（SVd）用于复发性/难治性多发性骨髓瘤的疗效和安全性, objectType=article, longId=151955, objectId=4deb1519558a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4deb1519558a, replyNumber=0, likeNumber=65, createdTime=2018-10-28, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4deb1519558a, moduleTitle=Blood：Selinexor联合低剂量硼替佐米和地塞米松（SVd）用于复发性/难治性多发性骨髓瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4deb1519558a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909711, encodeId=0d2f1909e11ef, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Blood：Brentuximab vedotin联合苯达莫司汀作为一线补救疗法用于复发性/难治性HL的疗效和安全性, objectType=article, longId=137013, objectId=ee2913e013e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee2913e013e6, replyNumber=0, likeNumber=70, createdTime=2018-06-12, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee2913e013e6, moduleTitle=Blood：Brentuximab vedotin联合苯达莫司汀作为一线补救疗法用于复发性/难治性HL的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee2913e013e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909719, encodeId=54a01909e198f, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Blood：Quizartinib单药治疗复发性/难治性FLT3-ITD突变型急性髓系白血病的效果和安全性, objectType=article, longId=140256, objectId=0af5140256d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0af5140256d5, replyNumber=0, likeNumber=110, createdTime=2019-02-17, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0af5140256d5, moduleTitle=Blood：Quizartinib单药治疗复发性/难治性FLT3-ITD突变型急性髓系白血病的效果和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0af5140256d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909688, encodeId=7f49190968879, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Eur Respir J：无诱因肺栓塞后复发性静脉血栓栓塞的危险因素分析！, objectType=article, longId=126001, objectId=f403126001c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f403126001c4, replyNumber=0, likeNumber=74, createdTime=2018-03-02, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f403126001c4, moduleTitle=Eur Respir J：无诱因肺栓塞后复发性静脉血栓栓塞的危险因素分析！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f403126001c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909737, encodeId=3fd81909e3744, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Cancer：碳离子照射作为局部复发性鼻咽癌的挽救治疗，安全有效, objectType=article, longId=149008, objectId=d8ca149008d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8ca149008d6, replyNumber=0, likeNumber=65, createdTime=2019-03-22, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8ca149008d6, moduleTitle=Cancer：碳离子照射作为局部复发性鼻咽癌的挽救治疗，安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8ca149008d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909733, encodeId=4df81909e33e4, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=2018 BSG/HIS指南：粪菌移植治疗复发性难治性艰难梭菌感染以及其他潜在并发症, objectType=article, longId=148088, objectId=59d014808817, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59d014808817, replyNumber=0, likeNumber=16, createdTime=2019-07-04, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59d014808817, moduleTitle=2018 BSG/HIS指南：粪菌移植治疗复发性难治性艰难梭菌感染以及其他潜在并发症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59d014808817)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909710, encodeId=b0bd1909e102a, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Blood：PI3Kδ抑制剂（INCB040093）单独或联合JAK1抑制剂（itacitinib）用于复发性/难治性B细胞淋巴瘤的安全性和疗效研究, objectType=article, longId=136587, objectId=884f13658e71, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=884f13658e71, replyNumber=0, likeNumber=92, createdTime=2018-08-27, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=884f13658e71, moduleTitle=Blood：PI3Kδ抑制剂（INCB040093）单独或联合JAK1抑制剂（itacitinib）用于复发性/难治性B细胞淋巴瘤的安全性和疗效研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=884f13658e71)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909745, encodeId=c9501909e458b, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Blood：卡非佐米相比硼替佐米可延长复发性/难治性多发性骨髓瘤患者的无进展存活期和总体存活期，且不受基础肾功能影响, objectType=article, longId=154529, objectId=b94515452947, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b94515452947, replyNumber=0, likeNumber=77, createdTime=2019-02-02, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b94515452947, moduleTitle=Blood：卡非佐米相比硼替佐米可延长复发性/难治性多发性骨髓瘤患者的无进展存活期和总体存活期，且不受基础肾功能影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b94515452947)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909729, encodeId=514a1909e2964, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Blood：来那度胺联合obinutuzumab用于复发性/难治性滤泡性B细胞淋巴瘤的安全性和疗效, objectType=article, longId=145755, objectId=8b22145e5508, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b22145e5508, replyNumber=0, likeNumber=71, createdTime=2018-12-07, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b22145e5508, moduleTitle=Blood：来那度胺联合obinutuzumab用于复发性/难治性滤泡性B细胞淋巴瘤的安全性和疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b22145e5508)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909692, encodeId=584f190969288, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Lancet Onco：希望！新药治疗复发性BRCA卵巢癌可产显著持久抗肿瘤活性！, objectType=article, longId=127553, objectId=9fd512e553f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fd512e553f9, replyNumber=0, likeNumber=62, createdTime=2018-09-21, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fd512e553f9, moduleTitle=Lancet Onco：希望！新药治疗复发性BRCA卵巢癌可产显著持久抗肿瘤活性！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fd512e553f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909734, encodeId=bd011909e3484, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Neurology：PD-1单抗对复发性高级别脑胶质瘤临床效果不佳, objectType=article, longId=148113, objectId=d8f314811387, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8f314811387, replyNumber=0, likeNumber=95, createdTime=2019-06-15, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8f314811387, moduleTitle=Neurology：PD-1单抗对复发性高级别脑胶质瘤临床效果不佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8f314811387)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909741, encodeId=26141909e414f, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=CLIN CANCER RES：Plerixafor联合Bevacizumab治疗复发性高级别胶质瘤, objectType=article, longId=151583, objectId=b06a151583fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b06a151583fa, replyNumber=0, likeNumber=88, createdTime=2019-02-06, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b06a151583fa, moduleTitle=CLIN CANCER RES：Plerixafor联合Bevacizumab治疗复发性高级别胶质瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b06a151583fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

复发性

2020-05-29

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Gastroenterology：戊酸、粪便微生物移植与复发性梭状芽胞杆菌感染

2018-12-24

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Lancet oncol：Axicabtagene ciloleucel（自体抗CD19嵌合抗原受体T细胞疗法）治疗复发性/难治性大B细胞淋巴瘤的长期安全性和疗

2019-06-17

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Lancet oncol：色瑞替尼联合吉西他滨用于原发性难治性或复发性霍奇金淋巴瘤的安全性评估

2019-07-09

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

一例复发性胃出血的罕见原因

2018-12-14

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

JAMA Intern Med：减少复发性尿路感染反复多喝水能少吃药？！

2019-05-08

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Blood：复发性或难治性结节性淋巴细胞为主型霍奇金淋巴瘤的更佳治疗方案

2018-12-09

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Stroke：升高的中性粒细胞和存在颅内动脉狭窄增加了复发性卒中的风险

2019-04-02

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Blood：PD-1封闭可提高复发性/难治性经典霍奇金淋巴瘤患者的缓解率，并延长其缓解时间，但会增加其免疫毒性风险

2018-11-14

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Blood：Selinexor联合低剂量硼替佐米和地塞米松（SVd）用于复发性/难治性多发性骨髓瘤的疗效和安全性

2018-10-28

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Blood：Brentuximab vedotin联合苯达莫司汀作为一线补救疗法用于复发性/难治性HL的疗效和安全性

2018-06-12

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Blood：Quizartinib单药治疗复发性/难治性FLT3-ITD突变型急性髓系白血病的效果和安全性

2019-02-17

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Eur Respir J：无诱因肺栓塞后复发性静脉血栓栓塞的危险因素分析！

2018-03-02

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Cancer：碳离子照射作为局部复发性鼻咽癌的挽救治疗，安全有效

2019-03-22

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

2018 BSG/HIS指南：粪菌移植治疗复发性难治性艰难梭菌感染以及其他潜在并发症

2019-07-04

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Blood：PI3Kδ抑制剂（INCB040093）单独或联合JAK1抑制剂（itacitinib）用于复发性/难治性B细胞淋巴瘤的安全性和疗效研究

2018-08-27

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Blood：卡非佐米相比硼替佐米可延长复发性/难治性多发性骨髓瘤患者的无进展存活期和总体存活期，且不受基础肾功能影响

2019-02-02

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Blood：来那度胺联合obinutuzumab用于复发性/难治性滤泡性B细胞淋巴瘤的安全性和疗效

2018-12-07

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Lancet Onco：希望！新药治疗复发性BRCA卵巢癌可产显著持久抗肿瘤活性！

2018-09-21

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Neurology：PD-1单抗对复发性高级别脑胶质瘤临床效果不佳

2019-06-15

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

CLIN CANCER RES：Plerixafor联合Bevacizumab治疗复发性高级别胶质瘤

2019-02-06

科室
- - 订阅+
  - 更多科室
工具
服务